Drug Trial Radar · NCT07148843
Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
105
Planned (sponsor's estimate)
Start
Oct 21, 2026
Primary completion
Oct 31, 2030
Study completion Oct 31, 2030
Sponsor
- Lead sponsor
- Johns Hopkins UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- First posted
- Aug 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cannabidiol (CBD), one of the most prevalent cannabinoids in cannabis (marijuana) has been shown to reduce alcohol withdrawal symptoms in laboratory animals. In people without alcohol use disorder (AUD), CBD has been show to be effective in reducing anxiety, sleep problems, and seizures; all of these are common symptoms of alcohol withdrawal. This randomized placebo-controlled clinical trial will evaluate the potential of CBD to improve alcohol withdrawal symptoms and reduce craving during acute abstinence among individuals with moderate-to-severe AUD. Adult participants with moderate-to-severe AUD will be admitted to an inpatient research unit at the Johns Hopkins Hospital for a 5-day, 4-night stay that includes alcohol abstinence with management of their alcohol withdrawal. In addition to standard care, participants will receive CBD or placebo (no CBD), complete assessments of withdrawal, sleep quality and provide breath and blood samples.
Conditions
- Alcohol Use Disorder (AUD)
- Withdrawal From Addictive Substance; Detoxification
- Craving
Interventions
Cannabidiol (CBD)Drug
Cannabidiol
PlaceboDrug
placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak score on the Alcohol Withdrawal Symptom Checklist (AWSC)Time frame: Four times daily during inpatient stay (4 nights)
- Peak score on the Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar)Time frame: 4 times daily during inpatient stay (4 nights)
- Average total sleep time (minutes) and wake after sleep onset as measured by wrist actigraphyTime frame: 4 nights during inpatient stay
- Peak alcohol craving as measured by scores on the Alcohol Urge Questionnaire (AUQ)Time frame: Four times daily during inpatient stay (4 nights)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Behavioral Pharmacology Research Unit
Baltimore, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.